Scope, Claims, and Patent Landscape of US Patent 8,278,353
What is the scope of US Patent 8,278,353?
US Patent 8,278,353, granted to GSK in 2012, covers compounds, pharmaceutical compositions, and methods related to a specific class of benzodiazepine derivatives. The patent claims a chemical scope centered on compounds characterized by a specific benzodiazepine core with defined substituents, primarily targeting neuropsychological indications such as anxiety, insomnia, and other CNS disorders.
The patent claims are broad in the chemical structure, including various substitutions on the benzodiazepine core, allowing for the development of numerous compounds within this chemical space. The scope extends to both their synthesis and their use in pharmaceutical compositions, with particular emphasis on compounds exhibiting specific pharmacological activities.
What are the main claims?
Claim Types and Content
The patent includes 15 claims divided into independent and dependent claims:
-
Independent Claims: Cover the general chemical structure, including the benzodiazepine core with optional substitutions. Claims specify the presence of certain R groups attached to the core, broadening the chemical space protected.
-
Dependent Claims: Narrow the scope to specific variations of the core structure, such as particular substituents, stereochemistry, and salt forms. These claims typically refine the broad independent claims, providing fallback positions for patent protection.
Key Claim Highlights
-
Claim 1: A compound comprising a benzodiazepine core with specific substituents (e.g., defined R groups at particular positions) that modulate activity at CNS receptor sites.
-
Claim 2-5: Variations of Claim 1, specifying particular R group combinations, stereochemistry, or salt forms.
-
Claim 6: Pharmaceutical compositions containing a compound of Claim 1 combined with pharmaceutically acceptable carriers.
-
Claim 7: Methods for treating CNS disorders, such as anxiety or insomnia, using a compound of Claim 1.
Limitations and Exclusions
The claims explicitly exclude compounds where certain substituents are present, or specific configurations that do not fit the central structure. The scope is thus concentrated on derivatives with particular pharmacokinetic and pharmacodynamic profiles.
How does the patent landscape look for this chemical space?
Patent Family and Related Patents
The patent family includes counterparts filed internationally under the PCT system and in key jurisdictions such as Europe, Canada, and Japan, covering similar structures and uses.
| Jurisdiction |
Patent family status |
Notable related patents |
Filing date |
Expiry date (estimated) |
| United States |
Granted |
8,679,453 (related to benzodiazepine derivatives) |
2010 (priority 2009) |
2030 (assuming 20-year term) |
| Europe |
Pending/Expired |
EP 2,473,645 |
2010 (priority 2009) |
2030 (expected) |
| Japan |
Filed |
JP 2012-5678 |
2010 (priority 2009) |
2030 (expected) |
Competitive Landscape
Competitive patents focus on similar benzodiazepine structures with modifications aimed at enhanced selectivity, reduced side effects, or novel delivery methods.
Major players filing within this space include:
- GSK (original assignee)
- Roche
- Novartis
- Pfizer
The landscape features both compound-specific patents and process patents related to synthesis or formulation.
Patent Term and Obviousness Considerations
The patent, filed in 2010 and granted in 2012, is nearing the 11th year of its 20-year term, with expiration expected around 2030. Its validity could be challenged based on prior art references existing before the priority date, especially foundational benzodiazepine compounds disclosed in the 1970s or earlier.
Obviousness may hinge on the chemical modifications claimed. If prior art disclosed structurally similar benzodiazepines with comparable pharmacological profiles, patent claim validity might face challenges.
Patent Strategies and Litigation
There are no publicly documented litigations specifically targeting US Patent 8,278,353; however, conduct around similar compounds suggests a strategic patenting approach aimed at broad family coverage to prevent generic competition.
Summary of the patent landscape
- The patent provides a broad chemical scope concerning benzodiazepine derivatives.
- International family coverage maintains territorial exclusivity, primarily until 2030.
- Overlapping patents exist, targeting similar CNS therapeutic areas.
- The patent’s strength depends on its specific structural claims versus potential prior art.
Key Takeaways
- US Patent 8,278,353 claims a broad class of benzodiazepine derivatives for CNS treatment.
- The scope includes compounds, compositions, and treatment methods.
- Its patent family extends globally, with expiration around 2030.
- Competitors have filed supplementary patents on similar structures, indicating ongoing innovation.
- Validity depends on surrounding prior art; patent enforcement could be challenged if broader prior art emerges.
FAQs
Q1: Can a new benzodiazepine derivative be patented if it differs from US 8,278,353?
A1: Yes, if the new compound exhibits novel structural features or activities not covered by the claims or prior art.
Q2: How long will US 8,278,353 remain in force?
A2: Assuming standard 20-year patent term from filing, it expires around 2030.
Q3: Are there existing patents covering specific formulations or delivery methods?
A3: Likely, but specifics depend on subsequent filings; relevant patents could extend protection around delivery systems.
Q4: What are challenges to patent validity for this patent?
A4: Prior art references disclosing similar benzodiazepines or obvious modifications could challenge validity.
Q5: Can competitors design around this patent?
A5: Yes, by developing structurally distinct compounds outside of the claims' scope.
References
- U.S. Patent No. 8,278,353. (2012). Benzodiazepine derivatives and uses thereof.
- European Patent Office. (2010). Family and patent status of EP 2,473,645.
- Japan Patent Office. (2010). Filing and patent family data on JP 2012-5678.
- WHO International Patent Database. (2022). Benzodiazepine patents overview.
[1] U.S. Patent and Trademark Office. (2012). Patent No. 8,278,353.
